Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AGI-1067: Phase III amended

AGIX plans to discontinue the 300 mg AGI-1067 arm of the placebo-controlled, double-blind, international

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE